Correlation of target kinase genotype with clinical activity of imatinib mesylate (IM) in patients with metastatic GI stromal tumors (GISTs) expressing KIT (KIT+)

Reviewer: Walter Sall, MD
Ultima Vez Modificado: 15 de mayo del 2005

Translation for this article does not exist


7 Tips for Giving Smart on #givingtuesday
by Christina Bach, MSW, LCSW, OSW-C
November 25, 2015

Related News

Data Point Out Why Certain Mutation in GI Tumor Occurs

Nov 26, 2015

In imatinib-resistant gastrointestinal stromal tumor patients, only Thr670Ile mutation is naturally selected at codon 670

Regorafenib Active in Metastatic GI Stromal Tumors

May 24, 2012

Significant activity for patients with advanced GIST after failure of imatinib and sunitinib

Longer Course of Imatinib Better in Trial for GI Stromal Tumor

Mar 28, 2012

Improves survival in post-op patients at high risk for recurrence of gastrointestinal stromal tumor